News
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
FIGEAC AÉRO: H1 2025/26 REVENUE €215.3 MILLION, IMPLYING 9.6% ORGANIC GROWTH 18th CONSECUTIVE QUARTER OF GROWTH IN LINE WITH THE FULL-YEAR TARGET
FIGEAC AÉRO: H1 2025/26 REVENUE €215.3 MILLION, IMPLYING 9.6% ORGANIC GROWTH 18th CONSECUTIVE QUARTER OF GROWTH IN LINE WITH THE FULL-YEAR TARGET
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF 2025
Kaufman & Broad SA: RESULTS OF THE FIRST NINE MONTHS OF 2025
FIGEAC AÉRO: FIGEAC AÉRO NORTH AMERICA AWARDED NEW CONTRACT BY BOMBARDIER
FIGEAC AÉRO: FIGEAC AÉRO NORTH AMERICA AWARDED NEW CONTRACT BY BOMBARDIER
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
FIGEAC AÉRO: FIGEAC AÉRO SECURES ITS LONG-TERM PARTNERSHIP WITH SAFRAN AIRCRAFT ENGINES
FIGEAC AÉRO: FIGEAC AÉRO SECURES ITS LONG-TERM PARTNERSHIP WITH SAFRAN AIRCRAFT ENGINES
FIGEAC AÉRO: FURTHER PROGRESS IN AEROSPACE POWER GENERATION WITH SAFRAN ELECTRICAL & POWER
FIGEAC AÉRO: FURTHER PROGRESS IN AEROSPACE POWER GENERATION WITH SAFRAN ELECTRICAL & POWER
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
RTL Luxemburg erweitert den Einsatz von Verimatrix-Technologien zum Schutz hochwertiger Automobilrennen vor Piraterie
Verimatrix, (Euronext Paris: VMX), ein führender Anbieter von Sicherheitslösungen für eine sicherere vernetzte Welt, gab heute bekannt, dass RTL Luxemburg, das führende Medienunternehmen des
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy
Regulatory News:
Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media
Verimatrix und Velocix schließen sich zusammen, um CDN-Piraterie zu bekämpfen
Regulatorische Nachrichten:
Verimatrix, (Euronext Paris: VMX), der führende Anbieter von Lösungen für eine moderne, vernetzte Welt mit menschenorientierter Sicherheit, gab heute eine
Verimatrix and Velocix Team Up to Fight CDN Piracy
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced a strategic collaboration with Velocix, the
EQS-News: Abivax Presents First Half 2025 Financial Results
EQS-News: Abivax Presents First Half 2025 Financial Results
FIGEAC AÉRO: Q1 2025/26 REVENUE: €101.9m, 10.3% ORGANIC GROWTH 17th CONSECUTIVE QUARTER OF GROWTH
FIGEAC AÉRO: Q1 2025/26 REVENUE: €101.9m, 10.3% ORGANIC GROWTH 17th CONSECUTIVE QUARTER OF GROWTH
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering